1. Home
  2. IRM vs INSM Comparison

IRM vs INSM Comparison

Compare IRM & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRM
  • INSM
  • Stock Information
  • Founded
  • IRM 1951
  • INSM 1988
  • Country
  • IRM United States
  • INSM United States
  • Employees
  • IRM N/A
  • INSM N/A
  • Industry
  • IRM Real Estate Investment Trusts
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • IRM Real Estate
  • INSM Health Care
  • Exchange
  • IRM Nasdaq
  • INSM Nasdaq
  • Market Cap
  • IRM 30.3B
  • INSM 29.0B
  • IPO Year
  • IRM 1996
  • INSM 2000
  • Fundamental
  • Price
  • IRM $100.35
  • INSM $140.54
  • Analyst Decision
  • IRM Strong Buy
  • INSM Strong Buy
  • Analyst Count
  • IRM 7
  • INSM 18
  • Target Price
  • IRM $120.14
  • INSM $146.81
  • AVG Volume (30 Days)
  • IRM 1.6M
  • INSM 2.2M
  • Earning Date
  • IRM 11-05-2025
  • INSM 10-30-2025
  • Dividend Yield
  • IRM 3.11%
  • INSM N/A
  • EPS Growth
  • IRM N/A
  • INSM N/A
  • EPS
  • IRM 0.14
  • INSM N/A
  • Revenue
  • IRM $6,443,114,000.00
  • INSM $398,105,000.00
  • Revenue This Year
  • IRM $12.75
  • INSM $31.95
  • Revenue Next Year
  • IRM $9.03
  • INSM $125.46
  • P/E Ratio
  • IRM $721.03
  • INSM N/A
  • Revenue Growth
  • IRM 10.72
  • INSM 21.15
  • 52 Week Low
  • IRM $72.33
  • INSM $60.40
  • 52 Week High
  • IRM $130.24
  • INSM $149.08
  • Technical
  • Relative Strength Index (RSI)
  • IRM 57.17
  • INSM 54.75
  • Support Level
  • IRM $100.38
  • INSM $134.01
  • Resistance Level
  • IRM $104.74
  • INSM $146.71
  • Average True Range (ATR)
  • IRM 2.50
  • INSM 3.80
  • MACD
  • IRM 0.22
  • INSM -2.01
  • Stochastic Oscillator
  • IRM 49.37
  • INSM 45.63

About IRM Iron Mountain Incorporated (Delaware)Common Stock REIT

Iron Mountain Inc is a record management services provider. It is organized as a REIT. Majority of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business; Global Data Center Business; and Corporate and Other Business. It generates maximum revenue from Global RIM Business segment.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: